| scholarly article | Q13442814 |
| P2093 | author name string | D R Hampson | |
| S Gholizadeh | |||
| L K K Pacey | |||
| P2860 | cites work | Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate | Q41166999 |
| Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome | Q41849184 | ||
| Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome | Q42530481 | ||
| Mechanisms of GABA release from human astrocytes | Q42730738 | ||
| Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes | Q42739394 | ||
| Astrocytes prevent abnormal neuronal development in the fragile x mouse. | Q43119646 | ||
| Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders | Q43246437 | ||
| Association of family history of autoimmune diseases and autism spectrum disorders. | Q44723499 | ||
| Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism | Q44748310 | ||
| Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures | Q46058214 | ||
| Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). | Q46205774 | ||
| Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism | Q48104813 | ||
| Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument | Q48116100 | ||
| Altered white matter fractional anisotropy and social impairment in children with autism spectrum disorder | Q50302149 | ||
| The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. | Q50312684 | ||
| Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. | Q50313330 | ||
| Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. | Q51820369 | ||
| Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. | Q51891210 | ||
| Tuberous sclerosis: a primary pathology of astrocytes? | Q80563726 | ||
| Maternal infection and immune involvement in autism | Q22252357 | ||
| Functional impact of global rare copy number variation in autism spectrum disorders | Q24596191 | ||
| Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism | Q24620573 | ||
| FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism | Q24631425 | ||
| Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice | Q24651541 | ||
| Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability | Q28240095 | ||
| Connecting genes to brain in the autism spectrum disorders | Q28705565 | ||
| Rare De Novo and Transmitted Copy-Number Variation in Autistic Spectrum Disorders | Q29394511 | ||
| Transcriptomic analysis of autistic brain reveals convergent molecular pathology | Q29614877 | ||
| The mGluR theory of fragile X mental retardation | Q29615060 | ||
| Dendritic spine pathology in neuropsychiatric disorders | Q29615871 | ||
| Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting | Q29616013 | ||
| Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes | Q29616326 | ||
| Reversal of neurological defects in a mouse model of Rett syndrome | Q29616452 | ||
| Neuroglial activation and neuroinflammation in the brain of patients with autism | Q29619689 | ||
| Potential therapeutic interventions for fragile X syndrome | Q30473378 | ||
| FMRP mediates mGluR5-dependent translation of amyloid precursor protein | Q33273636 | ||
| Bridging the gap between MRI and postmortem research in autism | Q33703072 | ||
| Open-label add-on treatment trial of minocycline in fragile X syndrome | Q33715073 | ||
| Repetitive behavior and increased activity in mice with Purkinje cell loss: a model for understanding the role of cerebellar pathology in autism | Q33758013 | ||
| Review of neuroimaging in autism spectrum disorders: what have we learned and where we go from here | Q33875887 | ||
| The immune system's role in the biology of autism | Q33966312 | ||
| hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies | Q34013644 | ||
| Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders | Q34024856 | ||
| Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway | Q34141979 | ||
| Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome | Q34142731 | ||
| Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. | Q34157712 | ||
| Fragile X and autism: Intertwined at the molecular level leading to targeted treatments | Q34198650 | ||
| Immune function of astrocytes | Q34398643 | ||
| Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome | Q34610850 | ||
| Antibodies against fetal brain in sera of mothers with autistic children | Q34727868 | ||
| Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links | Q34953710 | ||
| Regulation of gene expression in adeno-associated virus vectors in the brain | Q34987187 | ||
| Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration | Q34987845 | ||
| Further characterization of autoantibodies to GABAergic neurons in the central nervous system produced by a subset of children with autism | Q35027186 | ||
| IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation | Q35044553 | ||
| Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis? | Q36766427 | ||
| Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism | Q36859594 | ||
| Dysregulation of mTOR signaling in fragile X syndrome | Q36879282 | ||
| Immune transcriptome alterations in the temporal cortex of subjects with autism. | Q37218842 | ||
| GABA(A) receptor downregulation in brains of subjects with autism | Q37229115 | ||
| Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: an in situ hybridization study. | Q37299778 | ||
| Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome | Q37341395 | ||
| Mitochondrial dysfunction in autism | Q37558748 | ||
| Immune proteins in brain development and synaptic plasticity. | Q37617631 | ||
| Innate and adaptive autoimmunity directed to the central nervous system | Q37617636 | ||
| Viral vector-mediated gene transfer for CNS disease | Q37687420 | ||
| Signaling mechanisms regulating synapse formation and function in mental retardation. | Q37736078 | ||
| Immune dysfunction in autism: a pathway to treatment | Q37774097 | ||
| Changing face of microglia | Q37807203 | ||
| Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. | Q37821219 | ||
| Psychopharmacology of autistic spectrum disorders in children and adolescents. | Q37833755 | ||
| Autism spectrum disorders--a genetics review | Q37847947 | ||
| Autism spectrum disorders and autistic traits: a decade of new twin studies | Q37857801 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autism spectrum disorder | Q1436063 |
| autism | Q38404 | ||
| P304 | page(s) | 189-200 | |
| P577 | publication date | 2011-12-28 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Pathways to drug development for autism spectrum disorders | |
| P478 | volume | 91 |
| Q26853603 | Autism spectrum disorders and neuropathology of the cerebellum |
| Q21245286 | Brain functional networks in syndromic and non-syndromic autism: a graph theoretical study of EEG connectivity. |
| Q47874564 | Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished - a cross-sectional analysis. |
| Q50313070 | Delayed myelination in a mouse model of fragile X syndrome |
| Q37708396 | Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes |
| Q30365865 | FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype. |
| Q36766675 | Focal brain inflammation and autism |
| Q37558440 | Neurobiologically-based treatments in Rett syndrome: opportunities and challenges |
| Q36186534 | Persistent astrocyte activation in the fragile X mouse cerebellum |
| Q38270928 | Pharmacogenomic medicine in autism: challenges and opportunities |
| Q34499370 | Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. |
| Q41060924 | Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials |
| Q64245388 | The Application of Adeno-Associated Viral Vector Gene Therapy to the Treatment of Fragile X Syndrome |
| Q30659465 | The BOLD signal and neurovascular coupling in autism |
| Q37598422 | The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
| Q21131214 | Therapeutic role of hematopoietic stem cells in autism spectrum disorder-related inflammation |
| Q42096144 | Transcranial magnetic stimulation (TMS) therapy for autism: an international consensus conference held in conjunction with the international meeting for autism research on May 13th and 14th, 2014. |
| Q41918439 | Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice |
| Q33785978 | Updated report on tools to measure outcomes of clinical trials in fragile X syndrome |
| Q28300252 | Use of transcranial magnetic stimulation in autism spectrum disorders |
| Q38038399 | What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders |
| Q38046662 | mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders |
Search more.